Analyst Price Targets — SLRC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 8:31 pm | Robert Dodd | Raymond James | $16.00 | $15.14 | StreetInsider | Solar Capital (SLRC) PT Lowered to $16 at Raymond James |
| March 11, 2025 12:39 pm | — | Compass Point | $17.25 | $17.26 | TheFly | SLR Investment price target raised to $17.25 from $16.50 at Compass Point |
| May 30, 2024 7:31 am | Casey Alexander | Compass Point | $15.50 | $16.29 | StreetInsider | Solar Capital (SLRC) PT Raised to $15.50 at Compass Point |
| November 9, 2022 5:46 am | Casey Alexander | Compass Point | $15.75 | $13.97 | StreetInsider | Compass Point Upgrades Solar Capital (SLRC) to Buy |
| August 4, 2022 6:03 am | — | Raymond James | $16.50 | $14.70 | Benzinga | Raymond James Maintains Outperform on SLR Investment, Lowers Price Target to $16.5 |
| July 25, 2022 5:05 am | Finian O'Shea | Wells Fargo | $12.50 | $14.52 | TheFly | SLR Investment downgraded to Underweight from Equal Weight at Wells Fargo |
| April 25, 2022 9:38 am | — | Maxim Group | $20.00 | $17.11 | Benzinga | Maxim Group Initiates Coverage On SLR Investment with Buy Rating, Announces Price Target of $20 |
| April 25, 2022 8:54 am | — | Wells Fargo | $16.00 | $17.18 | Benzinga | Wells Fargo Maintains Equal-Weight on SLR Investment, Lowers Price Target to $16 |
Latest News for SLRC
SLR Investment Corp. (SLRC) Q4 2025 Earnings Call Transcript
SLR Investment (SLRC) came out with quarterly earnings of $0.4 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.44 per share a year ago.
Net Investment Income of $0.40 Per Share for Q4 2025; Stable NAV/Strong Credit Quality NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the “Company”, “SLRC”, “we”, “us”, or “our”) today reported net investment income (“NII”) of $21.6 million, or $0.40 per share, for the fourth quarter of 2025. On February 24, 2026, the Board declared a quarterly distribution of $0.41 per share…
SLR Investment (NASDAQ: SLRC - Get Free Report) and Advanced Medical Isotope (OTCMKTS:RDGL - Get Free Report) are both finance companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability. Analyst Recommendations This is a summary of
SLR Investment Corp. maintains a hold rating due to flat earnings, limited growth, and dividend coverage concerns, despite a more attractive price-to-NAV discount. SLRC's portfolio remains resilient, with low non-accruals (0.3% of fair value) and a high concentration in financials and healthcare, but sector concentration poses risk. Net investment income of $0.40/share fell short of the $0.41/share dividend, raising…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLRC.
U.S. House Trading
No House trades found for SLRC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.